Filed 12-4-08

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Attorney Docket No. 056291-5283	Application No. 10/578,663
	Applicants: **HENNEQUIN *et al.***	
PTO Form 1449 December 4, 2008	Filing Date: **January 17, 2007**	Group Art Unit: **1624**

U.S. PATENT DOCUMENTS

Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
	1.	US 2003/0186995	October 2, 2003	Kath et al.			
	2.	US 2004/0048880	March 11, 2004	Himmelsbach et al.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

Names

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	~~Class~~ ~~Sub-Class~~ ~~Translation~~
	3.	CA 2476008	October 9, 2003	Canada	Boehringer Ingelheim
	4.	CA 2543649	May 12, 2005	Canada	" "
	5.	WO 01/21596	March 29, 2001	WIPO	Astrazeneca Ltd.
	6.	~~WO 2004/046101~~	~~June 3, 2004~~	~~WIPO~~	
	7.	~~WO 2004/060846~~	~~January 22, 2004~~	~~WIPO~~	
	8.	~~WO 2005/013908~~	~~February 17, 2005~~	~~WIPO~~	
	9.	~~WO 2005/041973~~	~~May 12, 2005~~	~~WIPO~~	
	10.	~~WO 2003/097154~~	~~October 20, 2003~~	~~WIPO~~	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

11.	Ballard et al. "Developing a small molecule erbB2 inhibitor:challenges with optimising DMPK properties" Poster - Presented at DMDG Cambridge (February 6, 2008).
12.	Ballard et al. "Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorg Med Chem Lett. 17(22):6326-6329 (2007) .
13.	Barlaam et al. "A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(2):674-678 (2008) .
14.	Barlaam et al. "Indazolylamino/Anilinoquinazolines Bearing a C-5 substitution as erbB2 kinase inhibitors: Structure-activity relationships and identification of a candidate drug" at AACR in 2007.
15.	Barlaam et al. "Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(6):1799-1803 (2008) .
16.	~~Barlaam et al. "Indazolylamino/Anilinoquinazolines Bearing a C-5 Substitution As erbB2 Kinase Inhibitors: Structure-Activity Relationships and Identification of a Candidate Drug" Poster number P044 , presented at XXth International Symposium on Medicinal Chemistry (EFMC-ISMC 2008),Vienna, Austria, August 31 - September 4, 2008 .~~
17.	Cockerill et al. "Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2" Bioorganic & Medicinal Chemistry Letters 11(11):1401-1405 (2001).
18.	Ducray et al. "Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors" Bioorganic & Medicinal Chemistry Letters 18(3):959-962 (2008).
19.	Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13(4):637-640 (2003).
20.	Harris et al. "Systematic variation of a key quinazoline core" Presented at the XXII European Colloquium on Heterocyclic Chemistry (XXII ECHC-2006) Bari, Italy, September 2-6, 2006 .
21.	Hennequin et al. "N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor" J Med Chem. 49(22):6465-6488 (2006) .

Examiner	Date Considered
/Tamthom Truong/	04/09/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Crossed out references are those not provided.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Attorney Docket No. 056291-5283	Application No. 10/578,663
	Applicants: HENNEQUIN *et al.*	
PTO Form 1449 December 4, 2008	Filing Date: January 17, 2007	Group Art Unit: 1624

U.S. PATENT DOCUMENTS

Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Sub-Class	Translation

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	22.	Jani et al. "Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor" Cancer Research 67(20):9887-9893 (2007).
	23.	Klutchko et al. "Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors" J Med Chem. 49(4):1475-1485 (2006) .
	24.	Petrov et al. "Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series" Bioorg Med Chem Lett. 16(17):4686-4691 (2006) .

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

Examiner /Tamthom Truong/ Date Considered 04/09/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.